Vascular endothelial growth factor and its receptors in multiple myeloma

Area of Science:

• Oncology
• Hematology
• Angiogenesis Research

Background:

• Multiple myeloma (MM) transitions from an avascular to a vascularized state.
• This progression, termed active MM, involves increased bone marrow microvessel density.
• Tumor angiogenesis is a critical factor in cancer growth and metastasis.

Purpose of the Study:

• To review the literature on the role of vascular endothelial growth factor (VEGF) in MM progression.
• To discuss the implications of VEGF signaling in the transition to active MM.
• To summarize the therapeutic potential of antiangiogenic agents targeting VEGF in MM.

Main Methods:

• Literature review and synthesis of existing research.
• Analysis of studies investigating VEGF's role in MM angiogenesis.
• Examination of clinical data on anti-VEGF therapies for MM.

Main Results:

• VEGF is a key mediator in the development of the vascular phase of MM.
• Increased microvessel density in the bone marrow is associated with active MM.
• Antiangiogenic agents targeting VEGF signaling have demonstrated efficacy in preclinical and clinical studies.

Conclusions:

• VEGF plays a critical role in promoting the angiogenesis required for active MM.
• Targeting VEGF signaling represents a viable therapeutic strategy to inhibit MM progression.
• Further research into anti-VEGF therapies holds promise for improving MM patient outcomes.